Skip to Content

'
Ho-Young Lee, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Associate Professor, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
Professor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1992 Ewha Womans University, Seoul, Korea, Republic of, PHD, Pharmacology
1986 Ewha Womans University, Seoul, Korea, Republic of, MA, Pharmacology
1984 Ewha Womans University, Seoul, Korea, Republic of, BA, Pharmacology

Postgraduate Training

8/1995-4/1997 Research Fellowship, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Dr. Jonathan Kurie
3/1992-7/1995 Research Fellowship, Seoul National University, Cancer Research Center, Seoul, Korea, Republic of
3/1992-6/1995 Research Fellowship, Pusan National University, Department of Molecular Biology, Seoul, Korea, Republic of, Dr. Kim

Selected Publications

Peer-Reviewed Original Research Articles
1. Woo JK, Choi DS, Trans H, Gilbert BE, Hong WK, Lee HY. Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogens-and oncogenic K-ras-induced lung tumorigenesis. Can Prev Res 2(4):361-369, 4/2009. e-Pub 3/2009. PMCID: PMC2473316.
2. Kim W-Y, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 69(4):1624-32, 2/2009. e-Pub 1/2009. PMCID: PMC2646382.
3. Kim W-Y, Chang D-J, Hennessy B, Kang H-J, Yoo J, Han S-H, Kim Y-S, Park H-J, Seo S-Y, Mills G, Kim K-W, Hong WK, Suh Y-G, Lee H-Y. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res 1(7):577-587, 12/2008. PMID: 19139008.
4. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Berrino L, Lee HY, Heymach JV, Ciardiello F. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 216(3):697-707, 9/2008. PMID: 18381602.
5. Jin Q, Menter DG, Mao L, Hong WK, Lee H-Y. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 29(8):1614-1622, 8/2008. e-Pub 7/2008. PMCID: PMC2516487.
6. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 14(5):1581-9, 3/2008. PMID: 18316583.
7. Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, Hong WK, Lee HY. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 122(1):5-14, 1/2008. PMID: 17764071.
8. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67(24):11630-9, 12/2007. PMID: 18089792.
9. Peng X, Karna P, O'Regan RM, Wood WC, Lee H-Y, Yang L. Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharm 71(1):101-11, 1/2007. e-Pub 10/2006. PMID: 17035597.
10. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 5(11):2685-95, 11/2006. PMID: 17121915.
11. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66(20):10100-11, 10/2006. PMID: 17047074.
12. Schroeder CP, Kadara H, Lotan D, Woo JK, Lee HY, Hong WK, Lotan R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 66(19):9762-70, 10/2006. PMID: 17018636.
13. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239(1):136-43, 7/2006. e-Pub 9/2005. PMID: 16181731.
14. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12(2):653-61, 1/2006. PMID: 16428512.
15. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97(22):1695-9, 11/2005. PMID: 16288123.
16. Mann KK, Padovani AMS, Quo Q, Colosimo AL, Lee H-Y, Kurie JM, Miller, WH. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXR phosphorylation. J Clin Inv 115(10):2924-33, 10/2005. e-Pub 9/2005. PMCID: PMC1224295.
17. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97(17):1272-86, 9/2005. PMID: 16145048.
18. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11(16):6065-74, 8/2005. PMID: 16115952.
19. Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. J Clin Oncol 23(19):4439-49, 7/2005. PMID: 15994153.
20. Han JY, Liu DD, Lee JJ, Kurie J, Lotan R, Hong WK, Lee HY. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clin Cancer Res 11(6):2305-11, 3/2005. PMID: 15788681.
21. Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 96(20):1536-48, 10/2004. PMID: 15494604.
22. Lee HY. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. Biochem Pharmacol 68(6):1119-24, 9/2004. PMID: 15313408.
23. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23(39):6569-80, 8/2004. PMID: 15247904.
24. Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK, Kurie JM. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 10(13):1074-9, 2/2004. PMID: 14871987.

Invited Articles
1. Morgillo F, Lee HY. Development of Farnesyl Transferase Inhibitors as cancer agents: current status and future. Cancer Therapy 5:11-18, 1/2007. e-Pub 1/2007.
2. Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 15(6):709-19, 6/2006. PMID: 16732721.
3. Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8(5):289-310, 10/2005. e-Pub 9/2005. PMID: 16172017.

Last updated: 3/1/2010